You are here

Efficacy and Tolerability of Xalatan in Patients

Last updated on April 10, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Alexandria, , Egypt
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Glaucoma, Ocular Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patient with ocular hypertension at least 22mg Hg

- Patient must be over 18 years old

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- None listed in the protocol

NCT00950690
Pfizer
Completed
Efficacy and Tolerability of Xalatan in Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Familial Persistent Pulmonary Hypertension
NCT01720524
All Genders
0+
Years
Multiple Sites
Pulmonary Hypertension
NCT00946114
All Genders
18+
Years
Multiple Sites
Glaucoma, Ocular Hypertension
NCT01265719
All Genders
0+
Years
Multiple Sites
Efficacy and Tolerability of Xalatan in Patients
Observational Study Assessing The Efficacy And Tolerability Of Xalatan? In Patients With Open Angle Glaucoma And /Or Ocular Hypertension.
Efficacy data was not collected or analyzed. This study did assess safety and tolerability of Xalatan.
  • Efficacy data not collected or analyzed
  • Safety and tolerability of Xalatan assessed NA
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
adults with glauocma or ocular hypertension
  • Glaucoma
  • Ocular Hypertension
Drug: Xalatan 0.005% eye drops
ophthalmic solution dosed once daily for 3 months
Other Name: latanoprost
Study Drug - Xalatan 0.005% eye drops
Intervention: Drug: Xalatan 0.005% eye drops
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1289
December 2007
December 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient with ocular hypertension at least 22mg Hg
  • Patient must be over 18 years old

Exclusion Criteria:

  • None listed in the protocol
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Egypt,   Saudi Arabia,   United Arab Emirates
 
 
NCT00950690
A6111128
A6111128
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
February 2011

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now